Clinical Trials Directory

Trials / Completed

CompletedNCT00050349

EPO906 in Carcinoid and Other Neuroendocrine Tumors

EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.

Conditions

Interventions

TypeNameDescription
DRUGEPO906 epothilone B

Timeline

Start date
2002-07-01
Primary completion
2007-04-01
Completion
2007-04-01
First posted
2002-12-05
Last updated
2017-03-01

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00050349. Inclusion in this directory is not an endorsement.